HC Wainwright Issues Pessimistic Forecast for EPRX Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Equities research analysts at HC Wainwright cut their Q3 2025 earnings per share estimates for Eupraxia Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($0.20) per share for the quarter, down from their prior forecast of ($0.18). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.80) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($1.01) EPS, FY2028 earnings at ($1.04) EPS and FY2029 earnings at ($0.26) EPS.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05).

Other equities analysts have also issued reports about the company. Canaccord Genuity Group began coverage on Eupraxia Pharmaceuticals in a research report on Monday, June 16th. They set a “speculative buy” rating for the company. Cantor Fitzgerald began coverage on Eupraxia Pharmaceuticals in a research report on Thursday, July 24th. They set an “overweight” rating and a $11.00 target price for the company. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $11.00.

Eupraxia Pharmaceuticals Stock Up 0.8%

Eupraxia Pharmaceuticals stock opened at $5.32 on Friday. The stock has a 50-day simple moving average of $5.07 and a 200 day simple moving average of $4.12. Eupraxia Pharmaceuticals has a 12-month low of $2.20 and a 12-month high of $6.20. The stock has a market capitalization of $191.31 million, a price-to-earnings ratio of -6.26 and a beta of 1.50.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new position in shares of Eupraxia Pharmaceuticals during the 4th quarter worth about $31,000. Quadrature Capital Ltd acquired a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at approximately $61,000. Raymond James Financial Inc. acquired a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $37,000. Bank of America Corp DE grew its position in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Eupraxia Pharmaceuticals by 593.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after purchasing an additional 16,017 shares during the period.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.